-transparent.png){kind=logo}
Tetrandrine (TET), a traditional Chinese medicine, exerts remarkable anticancer activity on various cancer cells. However, little is known about the effect of TET on human prostate cancer cells, and the mechanism of function of TET on prostate cancer has not yet been elucidated. To investigate the effects of TET on the suppression of proliferation, induction of apoptosis, and inhibition of migration and invasion in human prostate cancer cell lines, DU145 and PC-3. Inhibition of growth was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and clone formation assay, and flow cytometry analysis was performed to detect the induction of apoptosis. Activation of poly (ADP-ribose) polymerase, caspase-3, Akt, phospho-Akt, Bcl-2, and Bax was analyzed by Western blotting. Wound healing assay and transwell migration assay were used to evaluate the effect of TET on migration and invasion of cancer cells. TET inhibited the growth of DU145 and PC-3 cells in a dose- and time-dependent manner. Cell cloning was inhibited in the presence of TET in DU145 and PC-3 cells. TET suppressed the migration of DU145 and PC-3 cells. Transwell invasion assay showed that TET significantly weakened invasion capacity of DU145 and PC-3 cells. TET exhibited strong inhibitory effect on proliferation, migration, and invasion of prostate cancer cells. In addition, TET induced apoptosis in a dose-dependent manner by activating the caspase cascade and inhibiting phosphoinositide 3-kinase-Akt signal pathway. The accumulating evidence suggests that TET could be a potential therapeutic candidate against prostate cancer in a clinical setting.
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
January 2016,
Cellular & molecular biology letters,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
January 2016,
Neoplasma,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
May 2021,
International journal of molecular medicine,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
April 2016,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
January 2021,
Evidence-based complementary and alternative medicine : eCAM,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
June 2020,
Anti-cancer drugs,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
November 2018,
Oncology letters,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
July 2012,
Oncology reports,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
January 2013,
Asian Pacific journal of cancer prevention : APJCP,
Wei Liu, and
Bo Kou, and
Zhen-Kun Ma, and
Xiao-Shuang Tang, and
Chuan Lv, and
Min Ye, and
Jia-Qi Chen, and
Lei Li, and
Xin-Yang Wang, and
Da-Lin He
September 2017,
Oncology research,
